Unstructured Recombinant Polymers for Protein Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying proteins with polymers, such as PEGylation, face challenges in site-specific conjugation, product mixture separation, and immunogenicity, particularly with pathogen-derived sequences, which require optimization for pharmacological applications.
Innovation Solution
Development of unstructured recombinant polymers (URPs) comprising at least 40 contiguous amino acids with specific residue compositions and structures, capable of extending serum half-life and solubility, and reducing immunogenicity when incorporated into proteins, allowing for the creation of multidomain products with enhanced properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If chemical conjugation of polymers to proteins is performed, then serum half-life and solubility are improved, but product mixture separation becomes difficult and manufacturing complexity increases
Solution Approach 1:
The invention divides the polymer modification process into two independent segments: (1) synthesis of defined-length polymer libraries with controlled structures, and (2) selection of optimal polymer-protein conjugates through screening. This segmentation allows each segment to be optimized independently, reducing overall manufacturing complexity while maintaining the serum half-life extension benefit.
Solution Approach 2:
The invention performs preliminary synthesis and characterization of polymer libraries with defined lengths and structures before conjugation to proteins. This preliminary action creates a pre-optimized set of polymer candidates, eliminating the need for complex separation and characterization of mixture products during final manufacturing, thus reducing manufacturing complexity while preserving half-life extension capabilities.
2Manufacturing precision
If site-specific PEGylation is performed, then product homogeneity is improved, but process control difficulty and manufacturing complexity increase
Solution Approach 1:
The invention introduces an intermediary screening step between polymer synthesis and final protein conjugation. This intermediary step involves selecting optimal polymer candidates from a library based on their ability to form homogeneous conjugates, thereby simplifying the overall process control while maintaining product homogeneity. The intermediary screening acts as a buffer that decouples the complexity of site-specific conjugation from the final manufacturing process.
3Duration of action of stationary object
If pathogen-derived sequences are used for polymer modification, then serum half-life is extended, but immunogenicity increases
Solution Approach 1:
The invention systematically varies key parameters of the polymer sequences (amino acid composition, length, charge distribution, and structural flexibility) to identify optimal configurations that extend serum half-life while minimizing immunogenicity. By treating sequence parameters as可调 variables rather than fixed pathogen-derived sequences, the invention finds parameter combinations that decouple half-life extension from immunogenicity.
Solution Approach 2:
The invention applies local quality optimization by modifying specific regions of the polymer sequences independently. Rather than using uniform pathogen-derived sequences, the invention optimizes local sequence characteristics (such as hydrophilic regions, charge distributions, and flexible segments) to achieve half-life extension in specific areas while minimizing immunogenic epitopes in other regions, thereby reducing overall immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
URPs significantly increase the serum half-life and solubility of proteins, reduce immunogenicity, and facilitate the production of proteins with improved stability and therapeutic efficacy by incorporating them into heterologous proteins, leading to enhanced pharmacological properties.
Implementation Method 1
These polymers exert their effect by increasing the hydrodynamic radius (also called Stokes' radius) of the modified protein relative to the unmodified protein, which reduces the rate of clearance by kidney filtration
Implementation Method 2
In addition, polymer attachment can reduce interaction of the modified protein with other proteins, cells, or surfaces
Data Source
AI summary
The present invention provides methods of using unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities, and the uses thereof. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.